Top London Pharmaceutical Companies (60)
Cencora is a leading pharmaceutical solutions organization centered on improving the lives of people and animals everywhere. With 46,000+ global team members, we have the opportunity to make a positive impact on healthcare in communities everywhere. Our team members are empowered to activate their careers through a collective of tools and resources designed to support individual career interests and aspirations. We value our listening culture that actions real outcomes and our team members appreciate and recognize one another for contributions that are making a meaningful global impact. No matter what your role is here, the work we do together has meaning. When you join our team, you become a crucial part of a greater purpose. We’re committed to supporting you personally and professionally, so we can achieve more together at the center of health.
Flatiron Health is a healthtech company dedicated to helping cancer centers thrive and deliver better care for patients today and tomorrow. Through clinical and data science, we translate patient experiences into real-world evidence to improve treatment, inform policy, and advance research. Cancer is smart. Together, we can be smarter. Flatiron Health is an independent affiliate of the Roche Group.
At Regeneron we believe that when the right idea finds the right team, powerful change is possible. As we work across our expanding global network to invent, develop and commercialize life-transforming medicines for people with serious diseases, we’re establishing new ways to think about science, manufacturing and commercialization. And new ways to think about health. Connect with us so we can learn more about you, and you can learn more about our biopharmaceutical medicines. And join us, as we build a future we believe in. Please visit www.regeneron.com/social-media-terms for information on how to engage with us on social media. An important note about privacy: Regeneron is committed to your privacy and will not ask for sensitive personal information such as social security number, date of birth or bank account details via email or social media.
At Lifebit, we're pushing forward the frontiers of health and knowledge by democratising access to omics data. We enable all researchers, whether novice or advanced, to run complex analyses and generate meaningful insights fast. Lifebit CloudOS is the world’s first federated genomics platform for unified and secure research over distributed big data - wherever data resides. From top tier pharmaceutical organisations to global research institutes to genetics companies and more, Lifebit CloudOS leads the way with our best-in-class UX/UI, seamless integration to open-source tools, marketplace of proprietary ones, powerful cohort browser, and advanced AI functionality. At Lifebit, we are open source pioneers, innovators redefining our industry. Our driving mission - to revolutionise bioinformatics and biomedical data analysis forever. We are growing fast and looking for more superstars to join our team.
We are a biopharmaceutical company and wholly owned subsidiary of Alfasigma S.p.A. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, including primary biliary cholangitis (PBC) and severe alcohol-associated hepatitis (sAH). In a new age of liver disease treatment, our team is developing vital therapies to meet the needs of those living with rare and serious liver disease. We are committed to improving patients’ lives and addressing the liver community’s most pressing needs. Our corporate headquarters is located in New Jersey. For more information about Intercept, please visit our website at: www.interceptpharma.com and follow us on X at: @InterceptPharma.
Symmetron is an established boutique health economics and health outcomes research consultancy that helps companies realise and communicate the value of their drugs and devices. Our mission is to increase access to healthcare that saves lives and improves quality of life for people around the world. We provide a full range of services for clients seeking market access and reimbursement in Europe, North America, Asia and Australia, including: • Evidence development • Health economic modelling • Health technology assessment • Statistical analysis of trial data • Scientific writing • Training and workshops We have experienced significant success since 2008, achieving market access for dozens of healthcare products and launching several blockbuster pharmaceuticals. We have published over 100 scientific articles, expanded our core service offerings and enjoyed steady growth fueled by the reputation of our exceptional team. Clients tell us they repeatedly return to us and refer us because of our: • Team stability – ‘With Symmetron you know what team you're going to get, so you can always give a solid recommendation to others’ • Integrity, honesty and transparency – ‘It’s great to be able to talk to someone honest and practiced’ • Flexibility, agility and pragmatism – ‘Team thinks out of the box and can move quickly’ • Professionalism and technical expertise – ‘Always delivered rigorous research and rock-solid timely results’ • Partnership – ‘Symmetron felt more like an extension of our own team’
JUNE Medical Group is a women-owned medical devices company with offices in the UK, USA and Sweden. The company supplies selected products from leading manufacturers, and develops its own medical instruments, including the Galaxy II self retaining retractor – an extraordinary tool featuring the world’s first ever light attachment, Galaxy II™ LUX Approved Supplier: Galaxy II is already on the system in NHS Supply Chain, The Mount Sinai Hospitals, U.S. Department of Veterans Affairs approved (DAPA number is SP0200-21-H-0057) Circle Health Group, Baylor Scott & White Health The Queens Award for Enterprise: INNOVATION 2021 Women Owned Certified JUNE Medical incl Mosaic Surgical Manufacturing Most Trusted Surgical Medical Device Company 2022 - UK Best New Business 2015 UK Entrepreneur of the Year 2017 Growth Champion by Dept Int Trade 2019 Champions of Trade BAB /US Embassy UK 2021 UK CEO of the Year 2021
For 45 years, we’ve been creating high-quality medicines and making them accessible to the people who need them. We are a trusted, reliable partner and dependable source of over 760* high-quality generic, speciality and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe. We have 32 manufacturing plants, 8 R&D centres and c8,800 employees worldwide. *As of February 2023 Subscribe to our channel on YouTube https://youtube.com/@hikmapharmaceuticals5668 For all product information and enquiries, please contact us at PV@hikma.com
Dunad Therapeutics is a biopharmaceutical company focusing on the development of next-generation targeted oral protein degradation therapies. Dunad’s platform enables selective degradation via direct target modification using tunable mono-valent small molecules, allowing for the development of more drug-like, orally bioavailable and CNS-accessible protein degraders
A science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. We have three global businesses that research, develop and manufacture innovative pharmaceutical medicines, vaccines and consumer healthcare products. We aim to bring differentiated, high-quality and needed healthcare products to as many people as possible, with our three global businesses, scientific and technical know-how and talented people.
Cisiv’s technology platform is fit-for-purpose and enables Pharmaceutical and Medical Device companies to collect and manage safety and efficacy studies in the real world. Through our technology, organizations are able to expand their global reach and provide access to more patients. The platform, Baseline plus, spans every aspect of data collection and analysis as well as complex workflows for stakeholder engagement. This intuitive, modular web-based platform is highly configurable, providing unrivalled flexibility, no matter the scope or scale and has proven to reduce data management costs by 60%. Baseline Plus is an industry leading platform, including EDC, eConsent, ePRO, eCOA, eDiary, Surveys, Safety, e-Source, with functionality suitable for site-based, decentralized, and hybrid research. Currently, Cisiv’s intelligent platform is utilized by 90% of the top global pharmaceutical companies and has supported 200+ projects with pharma and biotech organizations.
Pulmocide is a biopharmaceutical company that specializes in tackling difficult-to-treat respiratory diseases. We focus on respiratory fungal infections that can be serious and life-threatening and have significant effects on patients’ quality of life. Our current clinical development focus is on treating patients who have not successfully responded to the standard of care and on the prophylactic treatment of lung transplant patients. Pulmocide’s innovative approach to drug development provides a novel potential therapy that has been specifically designed to treat the most common fungal lung disease, pulmonary aspergillosis. Opelconazole was designed for inhaled delivery to minimize systemic exposure and deliver a high concentration of drug with a long retention time at the site of infection. This approach could improve treatment outcomes in patients with fungal lung disease without increasing systemic side effects and without interactions with other medications. The Pulmocide team is well experienced in the discovery and development of inhaled therapies for respiratory and infectious disease indications. They have particular expertise in the identification of novel compounds that can be delivered directly to the lungs.
Boehringer Ingelheim is working on breakthrough therapies that transform lives, today and for generations to come. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term perspective. More than 52,000 employees serve over 130 markets in the three business areas, Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. Learn more at www.boehringer-ingelheim.com
Pear Bio is a computational biology company that uses organ-on-a-chip and computer vision technology to recreate, visualize and compute the human tumor microenvironment and its effects on cancer progression. We are building an atlas of cancer progression to help research hospitals/pharma test experimental drugs and to help clinicians evaluate potential treatment options for each patient to improve outcomes. Our technology is applicable across solid tumors and we are currently working on a pipeline of biomarker negative cancers, with triple negative breast cancer as the lead indication. Our team has experience in big pharma and R&D tools, and our medical advisory board includes oncologists from MD Anderson, Imperial College London, Stanford University Medical Center and UCSF.
Order, track and get reminders for your NHS prescriptions – all in one place. Plus, get your medicine delivered to your door for free
Grow Pharma is the leader in supplying unlicensed cannabis medicines in the UK. Grow Pharma was established by Grow Biotech and IPS Pharma, combining cannabis sector expertise with 18 years’ experience manufacturing and importing unlicensed medicines
Curium is the global leader in nuclear medicine, providing life-changing diagnostics and treatment to patients all over the world. We develop, manufacture and distribute world-class radiopharmaceutical products with a renewed focus on cancer, exploring untapped potential for new innovation. We build on remarkable foundations and a legacy of providing reliable and consistent nuclear solutions to tens of thousands of patients every day. Our proven heritage combined with a pioneering approach are the hallmarks from which we provide life-changing diagnostics and therapeutics. Our people are the root of the incredible impact they have. As part of our 2030 vision to become an oncology-focused nuclear medicine leader – both in diagnostics and therapy – we will expand our reach further into Japan and China, continuing to roll out our superior products to a global market. The impact of these investments on patients will be life changing. Our cancer focus is currently in Neuroendocrine Tumors (NETs) and prostate cancer PSMA. We are also working on leveraging the power of AI to improve image quality and accuracy; to identify patterns to help diagnose pathologies and of course to better support physicians. Our Promise We strive to make the impossible possible and to be an organization that will change the face of medicine. Our diverse group of industry experts is unified under one strong and singular focus – to develop, manufacture and supply revolutionary diagnostic and therapeutic radiopharmaceuticals to our customers around the globe with unrivaled reliability and superior service.
RxLogix is a one-stop-shop for all PV needs applying the most recent technology advances like machine learning, artificial intelligence, and best practice methodological approaches. After a thorough evaluation of commercially available signaling and analytical software vendors, the FDA selected RxLogix’s PV Surveillance Suite Platform, replacing their legacy FAERS signaling system. FDA has decided to implement RxLogix PV Surveillance Suite (Modules – PV Reports, PV Signal, PV Analytics, and PV Datahub) for advanced data analytics, signal detection, evaluation, signal management, and benefit-risk assessment. RxLogix experienced team of business and technology innovators work with Pharmacovigilance and Risk Management Professionals to help increase the compliance, productivity, and quality for the entire Drug Safety value chain thus ensuring patient safety. RxLogix highly values defiant bold thinkers entrenched in the world of science, medicine, and innovation. From a strategic perspective, RxLogix proactively seeks innovative solutions as preemptive strikes against second-rate thinking.
We’re an innovative and forward-thinking Commercial Pharma analytics startup based in the UK. Since 2014 we’ve been focusing our efforts on providing cutting edge input to pharmaceutical organisations throughout Europe and North America. By combining years of experience in healthcare, pharmaceutical and data , we provide a powerful tool for acquiring real actionable insights to Commercial strategy, Formulary status, Salesforce effectiveness, targeting & segmentation, Sales analytics and many more.
To create a healthier future for patients with life-threatening diseases, we are using our pioneering human extracellular matrix (ECM)-based discovery platform to develop a portfolio of programmes in fibrosis and solid tumours. Using human in vitro models that better recreate the natural cell microenvironment is transforming our ability to identify new targets, determine mechanisms of action, and increase the success rate of therapeutic candidates. We have pioneered the world’s first human extracellular matrix-based discovery platform to aid in the discovery of targets and biomarkers as well as drug profiling. Using our technology, we have a unique ability to study tissue- and disease-specific human ECM scaffolds, and to model diseases to study mechanisms of action. Our improved understanding of the role of the ECM in human enables the identification of more relevant drug targets and biomarkers. For drug discovery, we incorporate human ECM into our in vitro models, thereby recreating the natural cell microenvironment so that drug candidates can be tested in the context they will ultimately be used in. With the potential to predict the efficacy of candidates more accurately at an earlier stage, the platform can reduce late-stage clinical failures and accelerate discovery.
Work Your Passion. Live Your Purpose.
Industry
Work Your Passion. Live Your Purpose.
